drugset

drugset / Trial / NCT07254481

VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

NCT07254481 ↗

Phase 1 Recruiting 86 enrolled Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.

Timeline

Start: 2025-10-05
Primary completion: 2026-07
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VB19055	Unknown	—	Oral

Indications